ArticlePLoS neglected tropical diseases2015
Immunodiagnosis of paracoccidioidomycosis due to Paracoccidioides brasiliensis using a latex test: detection of specific antibody anti-gp43 and specific antigen gp43.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Paracoccidioidomycosis in the 21st century: Challenges and milestones.PLoS neglected tropical diseases · 2026Review
- Antigenemia and oral lesions in paracoccidioidomycosis: is there a correlation?Journal of applied oral science : revista FOB · 2026Article
- Strengthening Fungal Infection Diagnosis and Treatment: An In-depth Analysis of Capabilities in Honduras.Open forum infectious diseases · 2024Article
- Diagnosis of Human Endemic Mycoses Caused by Thermally Dimorphic Fungi: From Classical to Molecular Methods.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- ExploringFrontiers in veterinary science · 2024Article
- The story of Paracoccidiodes gp43.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Article
- Fast and cost-effective protocol to produce Paracoccidioides spp. antigensBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Evidence of Histoplasma capsulatum seropositivity and exploration of risk factors for exposure in Busia county, western Kenya: Analysis of the PAZ dataset.PLoS neglected tropical diseases · 2023Article
- Paracoccidioides and Paracoccidioidomycosis in the 21st Century.Mycopathologia · 2023Review
- Development of a Multiplex qPCR Assay for Fast Detection and Differentiation of Paracoccidioidomycosis Agents.Journal of fungi (Basel, Switzerland) · 2023Article
- Paracoccidioidomycosis: Current Status and Future Trends.Clinical microbiology reviews · 2022Review
- Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- Immunologic Diagnosis of Endemic Mycoses.Journal of fungi (Basel, Switzerland) · 2022Review
- A New Duplex PCR-Assay for the Detection and Identification ofJournal of fungi (Basel, Switzerland) · 2021Article
- Immunoproteomic Analysis Reveals Novel Candidate Antigens for the Diagnosis of Paracoccidioidomycosis Due toJournal of fungi (Basel, Switzerland) · 2020Article
- Molecular Tools for Detection and Identification ofJournal of fungi (Basel, Switzerland) · 2020Review
- Clinical and epidemiological features of paracoccidioidomycosis due to Paracoccidioides lutzii.PLoS neglected tropical diseases · 2019Article
- Galactofuranose antigens, a target for diagnosis of fungal infections in humans.Future science OA · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParacoccidioidomycosis (PCM) is a life-threatening systemic disease and is a neglected public health problem in many endemic regions of Latin America. Though several diagnostic methods are available, almost all of them present with some limitations. METHOD/PRINCIPLE
findingsA latex immunoassay using sensitized latex particles (SLPs) with gp43 antigen, the immunodominant antigen of Paracoccidioides brasiliensis, or the monoclonal antibody mAb17c (anti-gp43) was evaluated for antibody or antigen detection in sera, cerebrospinal fluid (CSF), and bronchoalveolar lavage (BAL) from patients with PCM due to P. brasiliensis. The gp43-SLPs performed optimally to detect specific antibodies with high levels of sensitivity (98.46%, 95% CI 91.7-100.0), specificity (93.94%, 95% CI 87.3-97.7), and positive (91.4%) and negative (98.9%) predictive values. In addition, we propose the use of mAb17c-SLPs to detect circulating gp43, which would be particularly important in patients with immune deficiencies who fail to produce normal levels of immunoglobulins, achieving good levels of sensitivity (96.92%, 95% CI 89.3-99.6), specificity (88.89%, 95% CI 81.0-94.3), and positive (85.1%) and negative (97.8%) predictive values. Very good agreement between latex tests and double immune diffusion was observed for gp43-SLPs (k = 0.924) and mAb17c-SLPs (k = 0.850), which reinforces the usefulness of our tests for the rapid diagnosis of PCM in less than 10 minutes. Minor cross-reactivity occurred with sera from patients with other fungal infections. We successfully detected antigens and antibodies from CSF and BAL samples. In addition, the latex test was useful for monitoring PCM patients receiving therapy. CONCLUSIONS/SIGNIFICANCE: The high diagnostic accuracy, low cost, reduced assay time, and simplicity of this new latex test offer the potential to be commercialized and makes it an attractive diagnostic assay for use not only in clinics and medical mycology laboratories, but mainly in remote locations with limited laboratory infrastructure and/or minimally trained community health workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.